Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer - Study Results

Study Type:	Interventional
Study Design:	Randomized, Open Label, Active Control, Parallel Assignment
Conditions:	Cancer Breast Cancer
Interventions:	Drug: Ixabepilone + Capecitabine Drug: Capecitabine

Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
PLEASE NOTE: Completed=number of participants completing ≥18 cycles of treatment; not completed=number of subjects coming off study treatment prior to completing at least 18 cycles, with specified reasons for coming off study treatment. Participants continued to be followed for overall survival.

Reporting Groups

	Description
Ixabepilone + Capecitabine	Ixabepilone in combination with capecitabine (combination group): Ixabepilone 40 mg/m2 administered as a 3-hour intravenous (IV) infusion on Day 1 of each cycle only, plus oral capecitabine 1000 mg/m2 twice a day (BID) (2000 mg/m2 daily dose) x 14 days, followed by 1 week of rest.
Capecitabine	Capecitabine alone: Capecitabine 1250 mg/m2 BID (2500 mg/m2 daily dose) x 14 days, followed by 1 week of rest.

Participant Flow: Overall Study

	Ixabepilone + Capecitabine	Capecitabine
STARTED	609	612
COMPLETED	15^[1]	15^[2]
NOT COMPLETED	594	597
Adverse Event	12	17
Death	8	18
Disease Progression/Relapse	270	388
Physician Decision	50	61
Lost to Follow-up	1	2
Study Drug Toxicity	179	66
Withdrawal by Subject	55	30
Still On Treatment	2	1
Not Treated	12	11
Ineligible	2	1
Noncompliance	2	1
New primary cancer	1	0
Impending surgery	0	1

[1]	Participants who received 18 or more cycles of treatment.
[2]	Participants who received 18 or more cycles of treatment.

Baseline Characteristics

Hide Baseline Characteristics

Reporting Groups

	Description
Ixabepilone + Capecitabine	Ixabepilone in combination with capecitabine (combination group): Ixabepilone 40 mg/m2 administered as a 3-hour intravenous (IV) infusion on Day 1 of each cycle only, plus oral capecitabine 1000 mg/m2 twice a day (BID) (2000 mg/m2 daily dose) x 14 days, followed by 1 week of rest.
Capecitabine	Capecitabine alone: Capecitabine 1250 mg/m2 BID (2500 mg/m2 daily dose) x 14 days, followed by 1 week of rest.

Baseline Measures

	Ixabepilone + Capecitabine	Capecitabine	Total
Number of Participants [units: participants]	609	612	1221
Age, Customized [units: participants]
<65 years	532	531	1063
≥65 years	77	81	158
<50 years	225	235	460
≥50 years	384	377	761
Age [units: years] Median ( Full Range )	53.0 ( 23.0 to 78.0 )	53.0 ( 24.0 to 81.0 )	53.0 ( 23.0 to 81.0 )
Gender [units: participants]
Female	609	612	1221
Male	0	0	0
Race/Ethnicity, Customized [units: participants]
American Indian or Alaska Native	1	2	3
Asian	90	69	159
Black or African American	25	21	46
White	480	502	982
Unknown or Not Reported	13	18	31
Karnofsky performance Status^[1] [units: units on a scale]
100	219	265	484
90	187	188	375
80	151	130	281
70	44	26	70
<70	2	2	4
not reported	6	1	7
Menopausal Status [units: participants]
Premenopausal	93	90	183
Perimenopausal	32	32	64
Postmenopausal	475	481	956
Not Reported	9	9	18
Organ Sites [units: participants]
Ascites	13	16	29
Bone	283	287	570
Brain	0	1	1
Breast	41	54	95
Chest Wall Mass	47	38	85
CNS	1	0	1
Cutaneous	64	57	121
Effusion	7	7	14
Intestine	1	1	2
Lymph Node	236	233	469
Mediastinum	54	52	106
Other	17	30	47
Pleura	86	84	170
Subcutaneous	23	24	47
Visceral, Liver	273	276	549
Visceral, Lung	221	217	438
Visceral, Other	24	26	50
Presence with at least 1 lesion [units: participants]	606	612	1218

[1]	Karnofsky Performance Scale Index measures a patient's functional impairment: 100-80=able to carry on normal activity and work, no special care; 70-50=unable to work; able to live at home and care for most personal needs with assistance; 40=unable to care for self; requires institutional or hospital care. Score reported in multiples of 10.

Outcome Measures

Show All Outcome Measures

1. Primary:

Overall Survival (OS) [ from date of randomization until death ]

Show Outcome Measure 1

2. Secondary:

Progression-Free Survival (PFS) [ every 6 weeks (± 3 days) from randomization while on treatment until documented progression ]

Show Outcome Measure 2

3. Secondary:

Response Rate (RR) [ every 6 weeks (± 3 days) from randomization while on treatment until documented progression ]

Show Outcome Measure 3

4. Secondary:

Duration of Response [ every 6 weeks (± 3 days) from randomization while on treatment until documented progression ]

Show Outcome Measure 4

5. Secondary:

Time to Response [ every 6 weeks (± 3 days) from randomization while on treatment until documented progression ]

Show Outcome Measure 5

6. Secondary:

Treatment-Related Safety Summary [ safety was assessed on a continual basis every cycle while on-treatment and every 4 weeks post treatment until toxicities resolved or were deemed irreversible. ]

Show Outcome Measure 6

7. Secondary:

Symptom Assessment Score Changes From Baseline for Functional Assessment of Cancer Therapy-Breast Symptom Index (FBSI) [ Baseline and prior to each 21-day cycle of treatment, and at first posttreatment follow-up assessment ]

Show Outcome Measure 7

Serious Adverse Events

Show Serious Adverse Events

Other Adverse Events

Hide Other Adverse Events

Time Frame	No text entered.
Additional Description	No text entered.

Frequency Threshold

Threshold above which other adverse events are reported	5%

Reporting Groups

	Description
Capecitabine	No text entered.
Ixabepilone + Capecitabine	No text entered.

Other Adverse Events

	Capecitabine	Ixabepilone + Capecitabine
Total, other (not including serious) adverse events
# participants affected / at risk	564	590
Blood and lymphatic system disorders
ANAEMIA ^†^A # participants affected / at risk	44/603 (7.30%)	69/595 (11.60%)
LEUKOPENIA ^†^A # participants affected / at risk	28/603 (4.64%)	85/595 (14.29%)
NEUTROPENIA ^†^A # participants affected / at risk	49/603 (8.13%)	159/595 (26.72%)
Gastrointestinal disorders
NAUSEA ^†^A # participants affected / at risk	243/603 (40.30%)	315/595 (52.94%)
VOMITING ^†^A # participants affected / at risk	168/603 (27.86%)	250/595 (42.02%)
DIARRHOEA ^†^A # participants affected / at risk	244/603 (40.46%)	266/595 (44.71%)
DYSPEPSIA ^†^A # participants affected / at risk	45/603 (7.46%)	51/595 (8.57%)
STOMATITIS ^†^A # participants affected / at risk	68/603 (11.28%)	118/595 (19.83%)
CONSTIPATION ^†^A # participants affected / at risk	73/603 (12.11%)	161/595 (27.06%)
ABDOMINAL PAIN ^†^A # participants affected / at risk	77/603 (12.77%)	88/595 (14.79%)
ABDOMINAL PAIN UPPER ^†^A # participants affected / at risk	47/603 (7.79%)	55/595 (9.24%)
General disorders
PAIN ^†^A # participants affected / at risk	20/603 (3.32%)	32/595 (5.38%)
FATIGUE ^†^A # participants affected / at risk	166/603 (27.53%)	272/595 (45.71%)
PYREXIA ^†^A # participants affected / at risk	66/603 (10.95%)	84/595 (14.12%)
ASTHENIA ^†^A # participants affected / at risk	72/603 (11.94%)	128/595 (21.51%)
OEDEMA PERIPHERAL ^†^A # participants affected / at risk	43/603 (7.13%)	63/595 (10.59%)
MUCOSAL INFLAMMATION ^†^A # participants affected / at risk	53/603 (8.79%)	79/595 (13.28%)
Investigations
WEIGHT DECREASED ^†^A # participants affected / at risk	104/603 (17.25%)	194/595 (32.61%)
WEIGHT INCREASED ^†^A # participants affected / at risk	47/603 (7.79%)	26/595 (4.37%)
HAEMOGLOBIN DECREASED ^†^A # participants affected / at risk	22/603 (3.65%)	44/595 (7.39%)
PLATELET COUNT DECREASED ^†^A # participants affected / at risk	13/603 (2.16%)	33/595 (5.55%)
NEUTROPHIL COUNT DECREASED ^†^A # participants affected / at risk	21/603 (3.48%)	67/595 (11.26%)
WHITE BLOOD CELL COUNT DECREASED ^†^A # participants affected / at risk	13/603 (2.16%)	44/595 (7.39%)
Metabolism and nutrition disorders
ANOREXIA ^†^A # participants affected / at risk	99/603 (16.42%)	183/595 (30.76%)
Musculoskeletal and connective tissue disorders
MYALGIA ^†^A # participants affected / at risk	22/603 (3.65%)	146/595 (24.54%)
BACK PAIN ^†^A # participants affected / at risk	62/603 (10.28%)	70/595 (11.76%)
BONE PAIN ^†^A # participants affected / at risk	45/603 (7.46%)	55/595 (9.24%)
ARTHRALGIA ^†^A # participants affected / at risk	30/603 (4.98%)	119/595 (20.00%)
MUSCULAR WEAKNESS ^†^A # participants affected / at risk	5/603 (0.83%)	30/595 (5.04%)
PAIN IN EXTREMITY ^†^A # participants affected / at risk	56/603 (9.29%)	112/595 (18.82%)
MUSCULOSKELETAL PAIN ^†^A # participants affected / at risk	37/603 (6.14%)	85/595 (14.29%)
Nervous system disorders
HEADACHE ^†^A # participants affected / at risk	73/603 (12.11%)	97/595 (16.30%)
DIZZINESS ^†^A # participants affected / at risk	50/603 (8.29%)	69/595 (11.60%)
DYSGEUSIA ^†^A # participants affected / at risk	14/603 (2.32%)	67/595 (11.26%)
HYPOREFLEXIA ^†^A # participants affected / at risk	17/603 (2.82%)	37/595 (6.22%)
PARAESTHESIA ^†^A # participants affected / at risk	45/603 (7.46%)	115/595 (19.33%)
NEUROPATHY PERIPHERAL ^†^A # participants affected / at risk	12/603 (1.99%)	46/595 (7.73%)
PERIPHERAL MOTOR NEUROPATHY ^†^A # participants affected / at risk	23/603 (3.81%)	56/595 (9.41%)
PERIPHERAL SENSORY NEUROPATHY ^†^A # participants affected / at risk	64/603 (10.61%)	258/595 (43.36%)
Psychiatric disorders
INSOMNIA ^†^A # participants affected / at risk	37/603 (6.14%)	84/595 (14.12%)
Respiratory, thoracic and mediastinal disorders
COUGH ^†^A # participants affected / at risk	68/603 (11.28%)	89/595 (14.96%)
DYSPNOEA ^†^A # participants affected / at risk	84/603 (13.93%)	99/595 (16.64%)
Skin and subcutaneous tissue disorders
RASH ^†^A # participants affected / at risk	25/603 (4.15%)	68/595 (11.43%)
ALOPECIA ^†^A # participants affected / at risk	20/603 (3.32%)	245/595 (41.18%)
DRY SKIN ^†^A # participants affected / at risk	39/603 (6.47%)	51/595 (8.57%)
ERYTHEMA ^†^A # participants affected / at risk	12/603 (1.99%)	34/595 (5.71%)
PRURITUS ^†^A # participants affected / at risk	17/603 (2.82%)	31/595 (5.21%)
NAIL DISORDER ^†^A # participants affected / at risk	77/603 (12.77%)	193/595 (32.44%)
SKIN HYPERPIGMENTATION ^†^A # participants affected / at risk	75/603 (12.44%)	79/595 (13.28%)
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME ^†^A # participants affected / at risk	412/603 (68.33%)	383/595 (64.37%)

^†	Indicates events were collected by systematic assessment.
^A	Term from vocabulary, MedDRA 10.1

More Information

Hide More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

The agreement is:

	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. Restriction Description: Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial’s primary publication.

Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

Results Point of Contact:

Name/Title: BMS Study Director
Organization: Bristol-Myers Squibb
e-mail: Clinical.Trials@bms.com

No publications provided

Responsible Party:	Bristol-Myers Squibb ( Study Director )
Study ID Numbers:	CA163-048
Study First Received:	May 7, 2004
Results First Received:	May 1, 2009
Last Updated:	November 16, 2009
ClinicalTrials.gov Identifier:	NCT00082433 History of Changes
Health Authority:	United States: Food and Drug Administration